Showing results (61-70 of 128) with videos related to
Sort By:
Pageof 13
Clinical Lung Cancer|August 6, 2013
Chemotherapy outcomes by histologic subtypes of non-small-cell lung cancer: analysis of the southwest oncology group database for antimicrotubule-platinum therapyKaren Kelly, Kari Chansky, Philip C Mack, et al.Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|November 4, 2009
EGFR mutations detected in plasma are associated with patient outcomes in erlotinib plus docetaxel-treated non-small cell lung cancerPhilip C Mack, William S Holland, Rebekah A Burich, et al.Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|February 26, 2009
The Src inhibitor AZD0530 blocks invasion and may act as a radiosensitizer in lung cancer cellsPhillip R Purnell, Philip C Mack, Clifford G Tepper, et al.Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|November 4, 2009
Phase II study of erlotinib in patients with locally advanced or metastatic papillary histology renal cell cancer: SWOG S0317Michael S Gordon, Michael Hussey, Raymond B Nagle, et al.Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|September 10, 2008
Lower osteopontin plasma levels are associated with superior outcomes in advanced non-small-cell lung cancer patients receiving platinum-based chemotherapy: SWOG Study S0003Philip C Mack, Mary W Redman, Kari Chansky, et al.Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|August 1, 2007
Sorafenib with interferon alfa-2b as first-line treatment of advanced renal carcinoma: a phase II study of the Southwest Oncology GroupChristopher W Ryan, Bryan H Goldman, Primo N Lara, et al.Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|September 2, 2008
Southwest Oncology Group phase II trial (S0341) of erlotinib (OSI-774) in patients with advanced non-small cell lung cancer and a performance status of 2Paul J Hesketh, Kari Chansky, Antoinette J Wozniak, et al.Cancer|April 23, 2014
A phase 2 cooperative group adjuvant trial using a biomarker-based decision algorithm in patients with stage I non-small cell lung cancer (SWOG-0720, NCT00792701)Gerold Bepler, Ralph G Zinner, James Moon, et al.Clinical Lung Cancer|November 10, 2021
EGFR High Copy Number Together With High EGFR Protein Expression Predicts Improved Outcome for Cetuximab-based Therapy in Squamous Cell Lung Cancer: Analysis From SWOG S0819, a Phase III Trial of Chemotherapy With or Without Cetuximab in Advanced NSCLCFred R Hirsch, Mary W Redman, James Moon, et al.The Oncologist|February 24, 2024
Real-World Clinical Performance of a DNA-Based Comprehensive Genomic Profiling Assay for Detecting Targetable Fusions in Nonsquamous NSCLCPhilip C Mack, Rachel B Keller-Evans, Gerald Li, et al.Pageof 13